Form 4: BioLargo Director Linda Park Acquires Shares Through Option Grant
SEC Form 4 Filing
BioLargo director Linda Park acquired 98,684 shares through an option grant as compensation for board service.
Summary
- Linda Park, a director at BioLargo, Inc., acquired 98,684 shares of common stock through an option grant.
- The option was granted on December 31, 2024, at an exercise price of $0.19 per share.
- This option was issued as payment for $18,750 in fees for her board service during the most recent quarter.
- The option was granted under the company's 2024 Equity Incentive Plan.
- Following this transaction, Ms. Park directly owns 893,017 shares of BioLargo common stock.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction of a director receiving stock options as compensation, which is generally viewed positively as it aligns interests. There are no indications of negative sentiment.
Positives
- The option grant aligns director compensation with company performance.
- The transaction increases the director's stake in the company, potentially aligning her interests with shareholders.
Industry Context
This is a standard practice for compensating board members, aligning their interests with the company's performance and shareholder value. It is common for companies to use equity-based compensation to attract and retain qualified directors.
Comparison to Industry Standards
- Equity compensation for board members is a common practice across various industries.
- The specific amount and terms of the option grant would need to be compared to similar companies in the same sector to determine if it is within industry norms.
- Companies like Xometry, Inc. and Nano Dimension Ltd. also use stock options as part of their compensation packages for directors.
Stakeholder Impact
- Shareholders may view this positively as it aligns the director's interests with the company's performance.
- The option grant does not have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2022-11-01 | Date of the Limited Power of Attorney granted by Linda Park to John R. Browning. |
| 2024-12-31 | Date of the option grant to Linda Park. |
| 2024-12-31 | Date the option becomes exercisable. |
| 2034-12-31 | Expiration date of the option. |
| 2025-01-03 | Date the Form 4 was signed by John R. Browning, attorney-in-fact. |
Keywords
BioLargo, director, Linda Park, stock options, equity compensation, Form 4, insider trading, board of directors
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.